Clinical Trial: Treatment of Patients With Nocturia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia
Brief Summary: The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
Detailed Summary:
Sponsor: Serenity Pharmaceuticals, Inc.
Current Primary Outcome: number of nocturic episodes [ Time Frame: 4 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: proportion of nights with less than or equal to one nocturic episode [ Time Frame: 4 weeks ]
Original Secondary Outcome: Same as current
Information By: Serenity Pharmaceuticals, Inc.
Dates:
Date Received: July 9, 2009
Date Started: June 2009
Date Completion:
Last Updated: April 24, 2014
Last Verified: April 2014